对simvastatin和vismodegib之间的药理动力学相互作用的机制性见解:对优化结合治疗在脑髓母细胞瘤中的影响
Chaonan Zheng1, Zining Song1, Xing Zou1
1Jiangsu Key Laboratory of Neuropsychiatric Diseases and Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China.
Biochemical and biophysical research communications
|November 7, 2025
概括
对心膜母细胞瘤的维斯莫迪吉布和西姆瓦斯塔丁联合治疗可能会减少有毒副作用. 维斯莫迪吉布通过抑制OATP1B1和CYP3A4来增强对simvastatin的暴露,可能降低维斯莫迪吉布剂量并减轻骨毒性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 药物新陈代谢 药物新陈代谢
背景情况:
- 异常的Sonic Hedgehog (Shh) 路径激活是脑髓母细胞瘤发病的一个关键驱动因素.
- 维斯莫迪吉布 (一种光滑抗体) 和simvastatin (一种胆固醇合成抑制剂) 显示出对脑髓母细胞瘤的协同增长抑制作用.
- 在测试剂量下,simvastatin不会引起显著的骨发育毒性,这表明它有可能减轻vismodegib的骨副作用.
研究的目的:
- 为了研究基于vismodegib和simvastatin在髓母细胞瘤治疗中的协同相互作用的药理动力学机制.
- 为了阐明vismodegib如何影响simvastatin的吸收,分布,新陈代谢和分泌 (ADME).
- 探索减少vismodegib剂量和减轻其相关的骨发育毒性的潜力.
主要方法:
- 在一次性口服同时使用后,对小鼠的vismodegib和simvastatin的药理动力学概况.
- 在体外研究评估vismodegib对有机离子载体聚1B1 (OATP1B1) 和细胞染色体P450 (CYP) 酶的影响.
- 使用的HepG2和CHO-OATP1B1细胞用于OATP1B1输送试验和SLCO1B1转录分析.
- 使用小鼠肝脏显微体进行CYP酶抑制研究和分子对接以获得机械洞察力.
主要成果:
- 同时使用显著增加了simvastatin和simvastatin酸的全身暴露 (AUC),分别是1.97倍和2.16倍.
- 减少了simvastatin和simvastatin酸的清除,分别为42.9%和53.5%,表明代谢受损.
- 维斯莫迪吉布抑制了OATP1B1运输 (IC50: 2.0 μM),降低了SLCO1B1转录的调节,并竞争性地抑制了西姆瓦斯酸的CYP3A4媒介代谢 (IC50: 15.8 μM).
- 分子对接预测了vismodegib通过固体阻碍抑制CYP3A4和OATP1B1.
结论:
- 维斯莫迪吉和西姆瓦斯塔丁表现出由OATP1B1和CYP3A4.4的双重抑制驱动的药理学协同作用.
- 这种相互作用增强了simvastatin的全身和组织暴露,为减少vismodegib剂量提供了一种策略.
- 这些发现为缓解骨毒性的临床可行的策略提供了机制基础,同时保持了儿科脑髓母细胞瘤的抗瘤疗效.
相关概念视频
Pharmacokinetics: Drug–Drug Interactions
332
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
332
Pharmacokinetics in Pediatric Patients: Drug Metabolism
182
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
182
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
189
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
189
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
234
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
234
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Factors Affecting Protein-Drug Binding: Drug Interactions
539
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
539


